digplanet beta 1: Athena
Share digplanet:


Applied sciences






















G. V. Prasad
జి.వి. ప్రసాద్
Dr Reddys leader GV Prasad.jpg
Residence Hyderabad, India
Nationality Indian
Ethnicity Telugu
Alma mater Purdue University
Illinois Institute of Technology
Alagappa College of Technology
Occupation CEO of Dr. Reddy's Laboratories
Religion Hindu
Relatives Kallam Anji Reddy (father-in-law)
Kallam Satish Reddy (brother-in-law)

G. V. Prasad (Telugu: జి.వి. ప్రసాద్) is an Indian business executive, and CEO of Dr. Reddy's Laboratories.[1][2] Prasad studied Chemical Engineering at the Alagappa College of Technology. After completing five semesters, he went on to the Illinois Institute of Technology in Chicago to complete the three remaining semesters. Prasad followed up the engineering degree with a one-year MBA at Purdue University. He won the 'Outstanding Senior Student' Award from the American Institute of Chemists, Chicago chapter in 1982. He earned his Masters in Industrial Administration from Purdue University a year later.[3]

His first exposure to the world of pharmaceuticals was in 1985 with Benzex Labs, a pharmaceutical enterprise that he co-founded. Benzex was later acquired by Dr. Reddys and Prasad returned to the construction business, only to come back to pharmaceuticals in 1990 – this time as the CEO and MD of Cheminor Drugs Ltd. In 2001, Cheminor Drugs merged with Dr.Reddy's Laboratories[4] and Prasad took over as the vice-chairman and CEO of the merged entity.[5]

Early life[edit]

Prasad, the second child of Syamala and Harischandra Reddy,[6] did his initial schooling at the Vidyaranya High School in Hyderabad, Andhra Pradesh, India. He later moved to his hometown, Nellore, where he finished his schooling at VR High School.[7]

Personal life[edit]

Prasad is married to Anuradha, the daughter of Kallam Anji Reddy, who is the founder of Dr Reddy's Labs.[8] Anuradha is the managing trustee of Dr Reddy's Foundation as well as the founder-director of Saptaparni, an organisation promoting the traditions and culture of India.[9]

Early career[edit]

After completing his Masters, Prasad returned to India and joined his father's construction business, immersing himself in various projects in Karnataka. In 1985, he co-founded Benzex Labs, an API manufacturing company, which was later acquired by Dr Reddy's. He briefly returned to the construction business before reappearing on the pharma landscape in 1990 as managing director of Cheminor Drugs Ltd. Fueled by a spirit of entrepreneurship, Prasad transformed Cheminor into a world class API and Generics manufacturer, largely through his focus on professionalism, good governance and transparency.

In 2001, Cheminor Drugs merged with Dr.Reddy's Laboratories and Prasad took over as the vice-chairman and CEO of the merged entity. Prasad is widely credited as the architect of Dr. Reddy's successful global generics strategy. He envisioned newer business platforms like the Custom Pharmaceutical business and Specialty pharmaceuticals and is dedicated to building the innovation side of the business.

Professional affiliations[edit]

  • AP State Committee, WWF-India
  • Member of the Advisory Board, Acumen Fund
  • Member of the Board, Infotech Enterprises Ltd.
  • Member of the Board, Diana Hotels, India
  • Member of the Board, Ocimum Bio Solutions
  • Member, American Chemical Society
  • Member, American Institute of Chemical Engineers
  • Served as Chairman of the CII National Committee on Environment and the Intellectual Property Committee (2006–2007)


External links[edit]

Original courtesy of Wikipedia: http://en.wikipedia.org/wiki/G._V._Prasad — Please support Wikipedia.
This page uses Creative Commons Licensed content from Wikipedia. A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.

2798 news items

Forbes India

Forbes India
Sun, 22 Nov 2015 18:37:30 -0800

hen Dr Reddy's Laboratories—India's second-largest drug maker by sales—crossed the billion-dollar turnover mark in 2006, its founder Dr Kallam Anji Reddy wrote a letter to his colleagues thanking them for their dedication. He shared his ambition for ...


Pharmaceutical Processing
Fri, 27 Nov 2015 07:11:15 -0800

Dr. Reddy's chief executive GV Prasad indicated that the company was in the process of shifting some of the products from the plants in question to other facilities and considering third-party assessment for its sites. PhillipCapital India analyst ...
Wed, 25 Nov 2015 20:35:29 -0800

Shares in Dr Reddy's Lab, India's second biggest drugmaker, crashed 10 per cent on Thursday after the US drug regulator warned the company about a possible import ban from three of its units under scanner for inadequate quality control. Shares in Dr ...


Thu, 03 Sep 2015 19:03:45 -0700

From betting big on developing cheaper copies of biotech drugs to spearheading a new venture to incubate start-ups, Dr Reddy's Laboratories Ltd's chief executive officer G.V. Prasad is focused on preparing the drug maker for the future. In an interview ...
Wed, 25 Nov 2015 10:45:00 -0800

In FY15, directors who had a high share of variable pay include Dr. Reddy's Satish Reddy (88 per cent), Dr. Reddy's GV Prasad (93 per cent), Grasim Industries and Idea Cellular's Kumar Mangalam Birla (almost 100 per cent) and Hero MotoCorp's Munjals ...

Business Today

Business Today
Thu, 05 Nov 2015 19:15:53 -0800

Dr Reddy's CEO G V Prasad said the company will respond with a comprehensive plan to address the observations by the US Food and Drug Administration. DRL stock plunged nearly 15 per cent on the BSE to close at Rs 3629.55 apiece on Friday.

Economic Times

Economic Times
Thu, 05 Nov 2015 21:33:53 -0800

"We take quality and compliance matters seriously and stand by our commitment to fully comply with cGMP (current good manufacturing practice) quality standards across all of our facilities," CEO GV Prasad said in a release to the stock exchanges. "We ...

FiercePharma Manufacturing

FiercePharma Manufacturing
Tue, 10 Nov 2015 06:02:21 -0800

Dr. Reddy's has been investing in more automated plants in hopes of impressing the FDA and avoiding the kinds of regulatory actions that have sidelined competitors' plants. It didn't work out like the Indian drugmaker had hoped. Last week, the FDA sent ...

Oops, we seem to be having trouble contacting Twitter

Support Wikipedia

A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia. Please add your support for Wikipedia!

Searchlight Group

Digplanet also receives support from Searchlight Group. Visit Searchlight